| Literature DB >> 26793051 |
Marisa Brum1, Christopher Cabib2, Josep Valls-Solé2.
Abstract
Transcranial magnetic stimulation (TMS) gives rise to muscle responses, known as motor evoked potentials (MEP), through activation of the motor pathways. Voluntary contraction causes facilitation of MEPs, which consists of shortening MEP latency, increasing MEP amplitude and widening MEP duration. While an increase in excitability of alpha motorneurons and the corticospinal tract can easily explain latency shortening and amplitude increase, other mechanisms have to be accounted for to explain the increase in duration. We measured the increase in duration of the MEP during contraction with respect to rest in a group of healthy volunteers and retrospectively assessed this parameter in patients who were examined in a standardized fashion during the past 5 years. We included 25 healthy subjects, 21 patients with multiple sclerosis, 33 patients with acute stroke, 5 patients with hereditary spastic paraparesis, and 5 patients with signs suggesting psychogenic paresis. We found already significant differences among groups in the MEP duration at rest, patients with MS had a significantly longer duration, and patients with stroke had significantly shorter duration, than the other two groups. The increase in MEP duration during voluntary contraction was different in patients and in healthy subjects. It was significantly shorter in MS and significantly longer in stroke patients. It was absent in the five patients with suspected psychogenic weakness. In patients with HSP, an abnormally increase in duration occurred only in leg muscles. Our results suggest that the increase in duration of the MEP during contraction may reveal the contribution of propriospinal interneurons to the activation of alpha motorneurons. This mechanism may be altered in some diseases and, therefore, the assessment proposed in this work may have clinical applicability for the differential diagnosis of weakness.Entities:
Keywords: contraction-induced facilitation; motor evoked potential; multiple sclerosis; psychogenic weakness; spastic paraparesis; stroke
Year: 2016 PMID: 26793051 PMCID: PMC4707281 DOI: 10.3389/fnins.2015.00505
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Demographic and general clinical characteristics of patients included in the retrospective study.
| Age | 67 (6.4) | 52 (3.1) | 49 (4.3) | 54 (2.4) |
| Gender (M/F) | 21/12 | 11/10 | 4/1 | 5/0 |
| Weakness (MCR) | 1–4 | 2–5 | 4–5 | 0–3 |
| Most imparied side | 14 R/19 L | 14 R/7 L | Bilateral | 4R/1L |
significantly higher than in the other groups.
In leg muscles.
As for the patients first expression, with no encouragement.
Figure 1MEPs in healthy control subjects at rest and during contraction, recorded in the first dorsal interosseous muscle to cortical stimulation (above) and cervical foraminal stimulation (below). Rest, Recorded at rest; Contr, Recorded during contraction. The vertical lines illustrate the methods used to measure the MEP tail as one of the aspects of MEP facilitation with contraction.
Data gathered from 10 newly recruited healthy volunteers on facilitation of the MEP with mild and strong voluntary muscle contractions.
| Onset latency (ms) | 21.5 (1.8) | 19.7 (1.3)* | 91.6 | 19.6 (1.1)* | 91.1 |
| Amplitude (mV) | 1.1 (0.6) | 4.1 (0.7)* | 372.7 | 4.4 (0.9)* | 401.0 |
| Duration (ms) | 12.7 (2.0) | 17.7 (3.3)a | 139.3 | 17.9 (3.9)* | 140.9 |
| Onset latency (ms) | 13.4 (1.1) | 13.3 (1.1) | 99.2 | 13.3 (1.0) | 99.2 |
| Amplitude (mV) | 0.9 (0.5) | 1.3 (0.6)* | 144.4 | 1.3 (0.7)* | 144.6 |
| Duration (ms) | 8.4 (1.7) | 8.8 (2.1) | 104.7 | 8.8 (2.2) | 104.8 |
Data are represented as mean and 1 standard deviation (within parenthesis). Data in the columns labeled % are the ratio between contraction and rest for mild and strong contractions. Asterisks refer to a significant difference (p < 0.05) with respect to rest, in the post-hoc analysis after one factor ANOVA.
Mean data on MEPs obtained at rest in the healthy subjects and patients included in the retrospective study.
| HV (25) | 21.3 (1.9) | 19.2 (1.4) | 90.14 | 3.1 (0.7) | 6.8 (2.7) | 219.35 | 13.1 (2.3) | 17.8 (2.3) | 135.88 |
| Stroke (33) | 23.6 (3.1) | 20.5 (2.2) | 86.86 | 0.7 (1.3) | 2.2 (3.1) | 307.14 | 9.3 (4.8) | 18.2 (3.1) | 195.70 |
| MS (21) | 25.5 (4.2) | 24.5 (3.3) | 96.08 | 1.4 (0.8) | 1.9 (2.2) | 135.71 | 19.4 (2.5) | 21.7 (3.7) | 111.86 |
| Psychogenic (5) | 21.1 (2.2) | 20.3 (3.0) | 96.21 | 1.7 (2.3) | 2.3 (3.5) | 135.29 | 14.0 (2.1) | 14.3 (2.3) | 102.14 |
| HSP (5) | 22.0 (3.1) | 19.9 (2.8) | 90.45 | 2.3 (1.5) | 4.8 (3.0) | 208.70 | 14.5 (2.9) | 19.1 (4.1) | 131.72 |
| HV TA (12) | 30.9 (2.8) | 28.5 (2.0) | 92.23 | 1.4 (1.0) | 2.9 (2.3) | 207.14 | 19.7 (4.5) | 29.4 (5.6) | 144.16 |
| HSP TA (5) | 35.8 (4.7) | 35.4 (4.1) | 98.88 | 0.5 (1.2) | 0.6 (1.8) | 115.38 | 35.9 (8.4) | 36.2 (9.9) | 100.83 |
Data are the mean and one standard deviation (within parenthesis) measured on the MEP recorded in the first dorsal interosseous (except for HV TA and HSP TA, which were recorded in the tibialis anterior). HV, Healthy volunteers; MS, Multiple sclerosis; HSP, Hereditary spastic paraparesis. The number in parenthesis in the first column refers to the number of patients included in the analysis.
Onset latency and duration are measured in ms; peak amplitude in mV. Percentage refers to the percentage of the MEP characteristics during contraction with respect to rest. Superindices a, b, and c refer to significant differences (p < 0.05) found in the comparison among the three groups with a sizeable sample (healthy subjects, patients with stroke, and patients with multiple sclerosis).
Significantly longer than in healthy subjects.
Significantly shorter than in healthy subjects.
Significantly longer/larger in MS than in stroke.
Significantly smaller/shorter in MS than in stroke.
Figure 2Examples of MEP recordings in first dorsal interosseous at rest and during contraction in multiple sclerosis patients (A), stroke patients (B), and psychogenic weakness patients (C).
Differences in MEP tail among groups of subjects.
| FDI | Control (25) | 4.7 (0.7) |
| MS (21) | 1.4 (1.2) | |
| Stroke (33) | 8.5 (1.8) | |
| Psychogenic (5) | 0.8 (2.1) | |
| HSP (5) | 4.5 (0.9) | |
| TA | Control (12) | 6.1 (1.1) |
| HSP (5) | 0.5 (0.9) |
Data are the mean calculated among all subjects of the same group. Superindices a and b refer to the statistical significance measured with the post-hoc comparison after one-factor ANOVA including all groups recorded in the same muscle.
Significantly shorter than in control subjects.
Significantly longer than in all other groups.
Figure 3MEPs recorded in the tibialis anterior muscle at rest and during voluntary contraction in a healthy subject (A) and an HSP patient (B).